A novel, stable high molecular weight urokinase: preliminary results.
In this study, we successfully performed local thrombolysis in 6 patients with peripheral arterial occlusions by using a novel high-molecular-weight urokinase. Mean duration of recanalization was 12.8 hours, mean fibrinogen consumption was relatively low (42%), reptilase time was relatively long (mean increase by 47%). These findings would suggest that the substance is highly effective, though systemic adverse reactions are mild.
Grabenwoeger
F
F
Department of Radiology, University of Vienna, Medical School, Wien, Austria.
Duma
S
S
Dock
W
W
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D012103:Batroxobin; D004355:Drug Stability; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D013917:Thrombin / Q000097:blood; D013927:Thrombosis / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D005340:Fibrinogen; D012103:Batroxobin; D013917:Thrombin; D014568:Urokinase-Type Plasminogen Activator